medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 1

<< Back Next >>

Ann Hepatol 2015; 14 (1)

Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study

Hoyos S, Escobar J, Cardona D, Guzmán C, Mena Á, Osorio G, Pérez C, Restrepo JC, Correa G

Language: English
References: 18
Page: 58-63
PDF size: 89.32 Kb.


ABSTRACT

Introduction. Hepatocellular carcinoma is the most common primary tumor of the liver and is diagnosed in more than a half million people worldwide each year. This study aims to assess factors associated with the recurrence and survival of patients with hepatocellular carcinoma and liver transplantation in a cohort of patients from Medellín, Colombia. Material and methods. This was a descriptive retrospective study of a consecutive series of liver transplant patients from the Pablo Tobon Uribe Hospital of Medellín from January 2004 to May 2013. Demographic, clinical, imaging, and pathology variables were analyzed. Results. Three hundred thirty liver transplants were performed during the study period, 54 cases (16.4%) had one or more hepatocellular carcinomas in the explant, and 79.6% of these patients were men. Cirrhotic patients had different etiologies, but most of them were due to alcohol abuse (22.2%), followed by hepatitis B virus infection (20.4 %), and hepatitis C virus infection (18.5%). In the pathology specimen, 51.9% had only one focus of hepatocellular carcinoma, 22.2% had two foci and 12.9% had three tumors. Recurrence of hepatocellular carcinoma occurred in 7.4% patients with an average time of 81 months. During follow-up, 25.9% of the patients died in an average time of 67.9 months (CI95 59.1-80.1 months). Conclusion. Recurrence and survival of patients with liver transplantation for hepatocellular carcinoma in this study had a similar behavior as that reported in the world literature. The factors associated with these outcomes were vascular invasion, poor tumor differentiation and satellitosis.


REFERENCES

  1. Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med 2007; 120: 194-202.

  2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2009 Sub (1973-2007). Bethesda, MD: National Cancer Institute; 2010.

  3. Boyle P, Levin B. World Cancer Report. Lyon: IARC Press; 2008, p. 350-7.

  4. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2008. Lyon, France: IARC; 2008.

  5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Ammatuna M, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.

  6. Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl 2006; 12: 1028-36.

  7. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.

  8. García M, Barcena R. Hepatocarcinoma y trasplante hepático. Rev Esp Enferm Dig 2006; 98: 891-8.

  9. Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, Levy GA, Greig PD, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006; 81: 1633-9.

  10. Pérez de Luque D, López Vallejos P, Montero Álvarez JL, Fraga Rivas E, Barrera Baena P, Costán Rodero G, Rufian Peña S, et al. Supervivencia del paciente trasplantado de hígado por hepatocarcinoma y riesgo de ocurrencia tumoral. Rev Esp Enferm Dig 2006; 98: 899- 906.

  11. Martínez Ares D, Suárez López FJ, Souto Ruzo J, Otero Ferreiro A, Gómez Gutiérrez M, González Conde B, Fernádez Sellés C, et al. Liver transplantation in patients with hepatocellular carcinoma: factors implicated in tumor relapse. Rev Esp Enferm Dig 2004; 96: 22-31.

  12. Ataide E, Machado R, Ribeiro M, Mattosinho T, Romani R, Escanhonela C, Boin I. Survival and tumor relapse rate according to alpha-fetoprotein level in patients submitted to liver transplantation. Arq Bras Cir Dig 2011; 24: 43-7.

  13. Hoyos S, Sierra C, Franco G, Guzmán C, Mena A, Osorio G, Perez JC, et al. Hepatocellular carcinoma and liver transplantation: the dilemma of false positive results in images. Presetned at ILCA Sixth Annual Conference (International Liver Cancer Association), Berlin, Germany. September 2012.

  14. Hoyos S, Jaramillo P, Guzmán C, Mena A, Osorio G, Pérez JC, Restrepo J, et al. Carcinoma hepatocelular y trasplante: correlación entre la evaluación preoperatoria y el resultado definitivo de anatomopatología. Rev Col Cir 2009; 24: 76-82.

  15. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.

  16. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19: 3-23.

  17. Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma: should we push the limits? Liver Transpl 2003; 9: 697-9.

  18. Schwartz M. Liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2004; 10: S81-s85.




2020     |     www.medigraphic.com